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Abstract

Summary. Background: Plasma alpha2-antiplasmin (α2AP) is a rapid and effective inhibitor of the
fibrinolytic enzyme plasmin. Congenital α2AP deficiency results in a severe hemorrhagic disorder due to
accelerated fibrinolysis. It is well established that in the presence of thrombin-activated factor XIII
(FXIIIa), α2AP becomes covalently ligated to the distal α chains of fibrin or fibrinogen at lysine 303 (two
potential sites per molecule). Some time ago we showed that α2AP is covalently linked to plasma
fibrinogen . That singular observation led to our hypothesis that native plasma factor XIII (FXIII), which
is known to catalyze covalent cross-linking of fibrinogen in the presence of calcium ions, can also
incorporate α2AP into fibrinogen in the circulation. Results and Conclusions: We now provide evidence
that FXIII incorporates I125-labelled α2AP into the Aα-chain sites on fibrinogen or fibrin. We also
measured the content of α2AP in isolated plasma fibrinogen fractions by ELISA and found that
substantial amounts were present (1.2–1.8 moles per mole fibrinogen). We propose that α2AP
becomes ligated to fibrinogen while in the circulation through the action of FXIII, and that its
immediate presence in plasma fibrinogen contributes to regulation of in vivo fibrinolysis.

Introduction

Plasma alpha2-antiplasmin (α2AP) is a rapid and effective serine protease inhibitor (serpin) of the
fibrinolytic enzyme plasmin1-4. When this inhibitor is absent from plasma, as occurs in congenital
homozygous α2AP-deficiency, a severe hemorrhagic disorder results that is characterized by increased
susceptibility of intravascular thrombi to fibrinolysis5-7. The fibrinolytic defect is reversible by the
addition of α2AP. It is well known that in the presence of thrombin-activated factor XIIIa (FXIIIa) the
inhibitor becomes covalently ligated (‘cross-linked’) to a single site, lysine 303, on the fibrin- or
fibrinogen Aα-chain8, 9. Unbound α2AP inhibits tPA-induced fibrinogenolysis; however, only after it has
been incorporated into fibrin via FXIIIa, is α2AP an effective inhibitor of fibrinolysis10-13. In addition,
plasmin that becomes bound to fibrin is protected from inhibition by unbound α2AP14, thus
emphasizing the importance of prior α2AP incorporation into fibrin(ogen) for effectively mediating
inhibition of fibrinolysis. Finally, α2AP is incorporated into fibrin at only 20% to 30% of the potentially
available lysine 303 sites15-17, suggesting that the unreactive sites may already be occupied or
otherwise unavailable for ligation.
There are two forms of α2AP in human plasma, a full length 464-residue protein with amino-terminal
methionine (Met-α2AP) that accounts for ∼30% of the total, the remainder being composed of a
shortened 452-residue form with amino-terminal asparagine (Asn-α2AP)18, 19. The proportions of the
two forms of α2AP in plasma are related to the R/W6 single nucleotide polymorphism, with R being
associated with higher Asn-α2AP levels20. Incorporation of Asn-α2AP into fibrin is 3–13 times greater
than with the full length precursor form, Met-α2AP21, 22, but otherwise both forms display the same
inhibitory activities.
A plasmin inhibitory activity like that of plasma α2AP was discovered in fibrinogen many years ago23,
although it was not identified as α2AP until much later when immunochemical analyses showed that
α2AP was a constituent of normal fibrinogen as well as a dysfibrinogenemic fibrinogen (fibrinogen
Cedar Rapids)24. These observations combined with prior knowledge that native non-thrombinactivated plasma factor XIII (FXIII) can efficiently introduce covalent cross-links into fibrinogen as well

as fibrin in the presence of calcium ions25, and the retrospective insight that α2AP is incompletely
incorporated into fibrin by FXIIIa15-17, suggested to us that the α2AP found in plasma fibrinogen might
have been incorporated in the circulation through the action of FXIII. In this present study we show
that substantial amounts of α2AP are present in circulating fibrinogen, and we present evidence that
this process is mediated by plasma FXIII. We also introduce the concept that ligation of α2AP to plasma
fibrinogen prior to initiation of clotting serves an important role in down-regulating the rate of
fibrinolysis.

Materials and methods

Chemicals and reagents were of the highest purity available. Trasylol (aprotinin) was obtained from
Miles Inc. (Kankakee, IL, USA), and DE-52 cellulose was from Whatmann Inc. (Clifton, NJ, USA). Human
α–thrombin (3188 μ mg−1) was obtained from Enzyme Research Laboratories (South Bend, IN, USA),
and fibrinogen was isolated from human citrated plasma pools (obtained through the BloodCenter of
Wisconsin) by glycine precipitation followed by sub-fractionation to ‘fraction I-2’ as described26. Most
Aα-chains in fraction I-2 fibrinogen are full length and therefore they contain the α2AP ligation site at
Aα303. This plasma fraction was further separated into fibrinogen 1 (γA,γA) and fibrinogen 2 (γA,γ′) by
ion exchange chromatography27. Des-αC fibrinogen (old terminology, ‘fraction I-9D’) was produced by
limited plasmin digestion of fibrinogen28, lacked ∼390 residues of the C-terminal region of the Aα
chain29, 30, and therefore lacked the sequence containing Aα303. Fibrinogen fraction I-2 from the
fibrinogen Cedar Rapids proposita, which previously had been demonstrated to contain α2AP24, was
also analyzed. FXIII was prepared from pooled plasma31 and assayed as FXIIIa on a FXIII-free fibrin
substrate (fibrin 1) in the presence of 10 mm CaCl2 as described25, 32. FXIII concentrations were
determined spectrophotometrically at 280 nm, using an absorbance coefficient (A1%
1cm , 280 nm) of
33
−1
13.8 . The specific activity was 2100 to 2300 Loewy u mg . Normal plasma levels of factor XIII are 80–
110 Loewy u mL−1. Recombinant Asn-α2AP comprised of 464 AA, was prepared as described34, and had
a mass of 50 583 Da. A portion of this material was labeled with 125I by a lactoperoxidase method35,
and stored at a stock concentration of 0.87 mg mL−1 (17 μm).

Incorporation of α2AP into fibrinogen or fibrin by FXIII

For investigating FXIII-mediated incorporation of α2AP, FXIII-free fibrinogen 1 (8.8 μm, final) in 50 mm
Tris, 100 mm NaCl, 5.0 mm CaCl2, 0.4 mm DTT, pH 7.4, was mixed with 125I-labeled α2AP (1.0 to 6.0
μm), and ligation initiated at room temperature by adding 100 Loewy u mL−1 FXIII (final). After 6 h
incubation, the reaction was terminated by adding an equal volume of 2-fold concentrated Laemmli
buffer containing 1%β-mercaptoethanol, and the products of the reaction were analyzed by SDS-PAGE
on 9% polyacrylamide gels employing a discontinuous buffer system36. Dried Coomassie Brilliant Bluestained gels were subjected to autoradiography using Kodak X-Omat film. Autoradiograms were
digitized on a CanoScan 9950F flat bed scanner (Canon USA Inc, Lake Success, NY, USA), and α2APcontaining bands quantified using Image J (http://rsb.info.nih.gov/ij/). Results from stained gels were
normalized against the Bβ region of the gel whereas results from autoradiograms were normalized
against known quantities of 125I-labeled α2AP run on identical gels. Control samples included 125Ilabeled α2AP, fibrinogen 1, and fibrinogen 1 plus FXIII without 125I-labeled α2AP. To determine the
amount of 125I-labeled α2AP that could be incorporated into cross-linked fibrin by FXIIIa, identical
samples were prepared and the reaction initiated by adding 100 Loewy u mL−1 FXIII and 0.5 u mL−1

thrombin. For determining incorporation rates, FXIII-free fibrinogen 1 (8.8 μm final) in 50 mm Tris, 100
mm NaCl, 5.0 mm CaCl2, 0.4 mm DTT, pH 7.4, was mixed with 125I-labeled α2AP (1.0 or 5.0 μm), and the
reaction initiated by adding 100 Loewy u mL−1 FXIII or FXIIIa (containing 0.5 u mL−1 thrombin). At
selected intervals of up to 18 h the incubation was terminated by adding an equal volume of 2X
Laemmli buffer containing 1%β-mercaptoethanol, and the products of the reaction were analyzed as
described above.

Immunoassay of fibrinogen and α2AP

Fibrinogen concentrations were determined by ELISA37 using biotinylated rabbit anti-human fibrinogen
IgG (Dako, Carpinteria, CA, USA) for tagging the fibrinogen that had been bound to wells. Antigen
loading, equilibration and processing conditions were the same as described below for α2AP detection.
Fibrinogen fraction I-2 (>97% coagulable) was used for constructing a standard curve at test
concentrations ranging from 20 to 0.0125 μg mL−1. In order to measure α2AP in fibrinogen-containing
samples, we applied fibrinogen at concentrations that were five to eight times higher (2.5–20 μg mL−1,
0.74–5.9 nm) than those usually used for obtaining a linear plot37. Thus, the amount of fibrinogen
bound to the plate was determined from a non-linear portion of the fibrinogen calibration curve.
To measure α2AP in fibrinogen-containing samples by ELISA, we first constructed an α2AP calibration
curve as follows: Asn-α2AP (0.125–1.5 μg mL−1) was added to immunoplates (MG Scientific, Pleasant
Prairie, WI, USA), incubated overnight at 4°C, washed with PBS, blocked with 2% non-fat dried milk in
PBS for 1 h at room temperature, and rinsed with 200 μL PBS-Tween 20 (0.05%). Washed plates were
then treated with goat anti-human α2AP (Nordic Immunology, Tilberg, The Netherlands) at 1:5000
dilution in PBS-Tween 20, incubated for 1 h at 37°C, and washed four times with PBS-Tween (0.05%).
Horseradish peroxidase-labeled rabbit anti-goat IgG (Zymed, South San Francisco, CA, USA) at 1:15
000 dilution was added, incubated for 1 h at 37°C, and washed with PBS-Tween. After the final rinse,
100 μL o-phenylenediamine (OPD) solution (Zymed, South San Francisco, CA, USA) in 0.22 m citric acid,
0.05 m sodium phosphate, pH 5.0 buffer, was added and incubated in subdued light at room
temperature for 10–15 min. The reaction was terminated with 50 μL 2 N H2SO4 and the plate read at
490 nm on a Versamax Plate Reader. For determining the α2AP content in fibrinogen-containing
specimens, replicate wells were processed exactly as described above for α2AP calibration. The amount
of α2AP in fibrinogen was expressed as a molar ratio.

Results
Incorporation of α2AP radioactivity into fibrinogen or fibrin

Earlier studies had demonstrated that native FXIII (FXIII) was able to cross-link fibrinogen in the
presence of calcium ions25, and these findings prompted us to investigate whether FXIII might also
incorporate α2AP into fibrinogen without requiring thrombin activation. Incubating fibrinogen at a
physiological concentration (8.8 μm) with 125I-labeled α2AP (1–6 μm) plus physiological concentrations
of FXIII (100 Loewy units mL−1), as assessed from autoradiograms of SDS-PAGE gels, showed new radiolabeled bands (Fig. 1, panel A). These corresponded to an α2AP/Aα-chain heterodimer (‘α2AP/Aα
chain’), an α2AP/Aα-Aα chain heterotrimer (‘α2AP/Aα dimer’) and an α2AP/Aα-chain heteropolymer
(‘α2AP/Aα polymer’). In the Coomassie stained gel, we found new bands corresponding to the
radiolabeled α2AP/Aα heterodimer and α2AP/Aα-chain heteropolymer positions, plus non-radiolabeled

γ-dimers (panel B). The α2AP/Aα-Aα chain heterotrimer position was faintly stained but readily
detected in the autoradiogram.

Figure 1 Incorporation of I125-labeled α2AP into fibrinogen in the presence of FXIII (panels A and B) or, after
adding thrombin to form FXIIIa and fibrin (panels C and D). Autoradiograms are shown in panels A and C and
corresponding Coomassie blue stained gels in B and D).

Adding thrombin to the reaction mixtures to convert fibrinogen to fibrin and to activate FXIII to FXIIIa
(Fig. 1, panels C and D) resulted in similarly higher molecular weight stained bands, but the vast
majority of radioactive α2AP had been incorporated into the α-polymer region rather than the α2AP/α
heterodimer or heterotrimer positions (panel C). Figure 2 shows densitometric scans of the Fig. 1
panels A and C gels. It is evident that the radioactivity incorporated into fibrinogen or fibrin increased
proportionately with the concentration of α2AP, and that incorporation into fibrin was slightly higher
than for fibrinogen at any given α2AP concentration. At the highest α2AP concentration that we
studied, only about 40% of the potential α2AP sites had been labeled.

Figure 2 Molar ratio of α2AP incorporation into fibrinogen (FXIII) or fibrin (FXIIIa) as a function of the
concentration of α2AP (μm). Data points are derived from densitometric scans of the gels in Fig. 1, panels A and
C.

We also studied time-dependent incorporation of radioactivity into fibrinogen at α2AP concentrations
of 1 and 5 μm (Fig. 3) as well as into fibrin. At the lower α2AP concentration, radioactively-labeled
α2AP/Aα chain polymers were detected in fibrinogen within 5 min (Fig. 3, panels A and B), and to a

similar extent in fibrin (gels not shown). Inspection and densitometric scans of these gels revealed that
incorporation into either fibrinogen or fibrin began to plateau at about 30 min. At 5 μmα2AP,
incorporation of radioactivity began to plateau at 15 min (Fig. 3, panels C and D) for fibrinogen as well
as fibrin (gels not shown). Densitometric scans of the fibrinogen or fibrin SDS-PAGE gels (Fig. 4)
indicated that maximal incorporation of radioactivity was about 0.25 moles per mole for fibrinogen,
and slightly greater for fibrin (∼0.30 moles per mole).

Figure 3 Incorporation of α2AP into fibrinogen at 1 and 5 μmα2AP, as a function of time in minutes (m) or hours
(h). Stained gels, left. Autoradiograms, right.

Figure 4 Molar ratio of α2AP incorporation into fibrinogen by FXIII or into fibrin by FXIIIa as a function of time
(min). The reaction is presented at an α2AP concentration of 5 μm. The data points for fibrinogen are based
upon the experiment shown in Fig. 3, whereas the gel for fibrin is not shown.

Fibrinogen α2AP content

The α2AP content in plasma fibrinogen fraction I-2 from four separate pools of normal citrated plasma
and that from the proposita of the Cedar Rapids dysfibrinogenemia (γ275R to C)24 was assessed by
immunoassay and is represented as the molar ratio of α2AP to fibrinogen (Table 1). Given the fact that
there is a single site at Aα303 on each Aα chain to which α2AP can become ligated8, 15-17, 38, the
maximum ratio of α2AP to fibrinogen is two. With the sole exception of des-αC fibrinogen, the negative
control, which lacks C-terminal portions of Aα chains containing the α2AP binding site, each of the
fibrinogen fractions tested contained α2AP. In every case, the α2AP:fibrinogen ratio was between one
and two, indicating that considerable amounts of α2AP had been incorporated into plasma fibrinogen,
a result that is consistent with earlier observations of the presence of α2AP in plasma fibrinogen23, 24.
As discussed in the next section, the α2AP content of Cedar Rapids fibrinogen was the same or possibly

even lower than that in normal fibrinogen, and thus did not account for delayed fibrinolysis that has
been observed in this fibrinogen24.
Table 1. α2AP/fibrinogen molar ratio
Fibrinogen fraction
n Ratio
�)
Normal fraction I-2
4 1.5 (X
Cedar Rapids fraction I-2 1 1.2
Des-αC fibrinogen
1 0

Range
1.25–1.8
–
0

Discussion

A plasmin inhibitory activity corresponding functionally to α2AP was discovered in plasma fibrinogen
many years ago23, although it was not specifically identified as α2AP until years later, when it was
shown by immunochemical analysis to be a constituent of normal fibrinogen as well as a
dysfibrinogenemic fibrinogen, fibrinogen Cedar Rapids24. This discovery suggested that α2AP might
have been incorporated covalently into fibrinogen through the action of a calcium ion-dependent
transglutaminase like FXIII, which circulates with fibrinogen in plasma. This postulation, combined with
prior knowledge that ‘native’ FXIII is an active enzyme that efficiently introduces covalent cross-links
into fibrinogen or fibrin molecules25, prompted us to investigate this possibility in detail. Our present
experiments confirm that α2AP is a covalently bound constituent of plasma fibrinogen, that it is present
in substantial amounts, and that plasma FXIII can mediate its incorporation into fibrinogen. These
findings support the hypothesis that α2AP becomes ligated to plasma fibrinogen in the circulation, and
is very likely to have been incorporated through the action of circulating FXIII.
We were particularly interested in quantifying the α2AP content in the Cedar Rapids dysfibrinogen24,
not only because members of this kindred had experienced severe thrombophilia associated with
delayed fibrinolysis, but also because Cedar Rapids fibrinogen had been the index case for measuring
the presence of α2AP in plasma fibrinogen; we were still seeking to explain that phenomenon in terms
of the α2AP content. Our present results confirm those in the first study, and indicate that the α2AP
content of Cedar Rapids fibrinogen is the same or possibly even lower than that in normal fibrinogen,
and thus cannot alone account for delayed fibrinolysis24. Another explanation will be required.
Although it is well established that in the presence of thrombin-activated FXIIIa, α2AP becomes ligated
to the fibrin or fibrinogen Aα-chain8, 9, 15-17, 38, it was not known prior to this study that native FXIII, in
addition to introducing covalent cross-links into fibrinogen or fibrin in the presence of calcium ions25,
can also incorporate α2AP into fibrinogen. The rate of α2AP incorporation into fibrinogen by FXIII was
nearly as rapid as the rate of incorporation into fibrin by FXIIIa. These findings provide an attractive
mechanistic explanation for why circulating fibrinogen contains α2AP. Furthermore, as the content of
α2AP in fibrinogen is so relatively high (i.e. 1.2–1.8 moles per mole fibrinogen (Table 1) it readily
explains why we (this study) as well as previous investigators found that the number of available sites
on Aα-chains for α2AP incorporation were only 20–30% of those potentially available15-17. In contrast to
the relatively high content of α2AP that we found in plasma fibrinogen few, if any, intermolecular
fibrin(ogen) γ chain cross-links are found in normal plasma, although substantial amounts of these
products occur under pathological circumstances, including subjects with familial Mediterranean
fever39 and disseminated intravascular coagulation syndromes40. Thus, the effective down-regulation

of FXIII-mediated fibrin(ogen) cross-linking in blood contrasts with the relatively high content of α2AP
in plasma fibrinogen, implying that this interaction is less effectively regulated.
Our present estimations for the α2AP content in fibrinogen are between 1.2 and 1.8 moles per mole
fibrinogen. Since the plasma fibrinogen level is ∼9 μm, the plasma concentration of α2AP that has been
incorporated in the fibrinogen compartment lies between 11 and 16 μm. The reported level of plasma
α2AP is, however, only ∼1 μm (17 inter alia), a value that vastly underestimates the total amount of
α2AP in plasma. The lower estimate is derived from radial immunodiffusion or rocket
immunoelectrophoresis measurements that would be mainly if not solely, a measure of ‘free’α2AP,
because these techniques are not likely to have taken into account the relatively large amount of more
slowly diffusing fibrinogen-bound α2AP. Thus, except for this present study and two earlier ones that
focused on the inhibitor content of fibrinogen itself (23, 24), the existence of α2AP covalently bound to
fibrinogen in plasma has been overlooked.
Congenital homozygous α2AP deficiency causes a severe hemorrhagic disorder characterized by
increased susceptibility of intravascular thrombi to fibrinolysis5-7, underscoring the importance of α2AP
for down-regulating fibrinolysis. Observations on this catastrophic hemorrhagic condition have not,
however, addressed an obverse possibility, namely that incorporation of α2AP into plasma fibrinogen
prior to the initiation of clotting and subsequent fibrinolysis, serves an important role in its own right in
down-regulating the rate of fibrinolysis. This notion is supported by the fact that α2AP is an effective
inhibitor of fibrinolysis only after it has been incorporated into fibrin10-13. The extent to which the α2AP
incorporation into fibrinogen varies from individual to individual remains to be investigated, but it is
tempting to speculate that the degree of α2AP incorporation plays an important role in the fibrinolytic
response in vivo. In summary, we propose that incorporation of α2AP into circulating fibrinogen prior
to initiation of blood clotting plays an important role in down-regulating fibrinolysis, thus suggesting a
new role for plasma FXIII in regulation of fibrinolysis.
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